TBI-223

DB18911InvestigationalSmall molecule

TBI-223 is under investigation in clinical trial NCT06192160 (Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis).

Chemical structure of TBI-223
Formula / weight
C17H20FN3O5 · 365.361 g/mol (avg)
Also known as
CARBAMIC ACID, N-(((5S)-3-(3-FLUORO-4-(2-OXA-6-AZASPIRO(3.3)HEPT-6-YL)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-, METHYL ESTER
Code names
TBI-223

Resolves to

Compound
UNIIB4RS1V5YSPCAS2071265-08-0
Structure
InChIKeyZNBRXLSWXJKKLJ-LBPRGKRZSA-NSMILESCOC(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(N2CC3(COC3)C2)C(F)=C1

What you can answer from here — as of April 23, 2025

2Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of TBI-223, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In